Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 8/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.36 |
| ▸ | JAK2 | O60674 | 2/20 | 0.32 |
| ▸ | JAK1 | P23458 | 2/20 | 0.32 |
| ▸ | TYK2 | P29597 | 2/20 | 0.32 |
| ▸ | JAK3 | P52333 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3771621 | 0.89 | SLC2A1 (0.47) | SLC2A1KCNH2MTNR1AMTNR1B | |
| SCHEMBL5263326 | 0.85 | SLC2A1 (0.36) | SLC2A1KCNH2KDM4ELMNAGLA | |
| SCHEMBL5262592 | 0.83 | SLC2A1 (0.37) | SLC2A1KCNH2MTNR1AMTNR1B | |
| SCHEMBL3781214 | 0.79 | KCNH2 (0.47) | SLC2A1KCNH2 | |
| SCHEMBL13014349 | 0.78 | KCNH2 (0.41) | SLC2A1KCNH2JAK2JAK1TYK2 | |
| SCHEMBL4760024 | 0.78 | KCNH2 (0.57) | KCNH2 | |
| SCHEMBL3784360 | 0.77 | KCNH2 (0.62) | SLC2A1KCNH2 | |
| SCHEMBL3771391 | 0.76 | KCNH2 (0.40) | SLC2A1KCNH2JAK2JAK1TYK2 | |
| SCHEMBL3771385 | 0.76 | KCNH2 (0.40) | SLC2A1KCNH2JAK2JAK1TYK2 | |
| SCHEMBL3780492 | 0.75 | KCNH2 (0.41) | SLC2A1KCNH2JAK2JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324030-A1 | 5-Quinoline derivatives having an anti-bacterial activity | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2010-12-23 | — | — | US | disclosed |
| EP-1943222-A1 | ANTIBACTERIAL ACTIVE 5-CHINOLIN DERIVATIVE | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007042325-A1 | ANTIBACTERIAL ACTIVE 5-CHINOLIN DERIVATIVE | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324030-A1 | 5-Quinoline derivatives having an anti-bacterial activity | TOP2A, TOP1, TOP2B | SLC2A1 4605/4885KCNH2 3216/4885JAK2 4772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.